- Home
- ETON vs PFL Comparison
ETON vs PFL Comparison
Compare ETON & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETON | PFL |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 374.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ETON | PFL |
|---|---|---|
| Price | $16.84 | $8.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $29.67 | N/A |
| AVG Volume (30 Days) | ★ 270.8K | 113.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.53% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,316,000.00 | N/A |
| Revenue This Year | $113.27 | N/A |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 102.77 | N/A |
| 52 Week Low | $11.09 | $6.98 |
| 52 Week High | $23.00 | $8.62 |
Technical Indicators
Market Signals| Indicator | ETON | PFL |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 42.94 |
| Support Level | $16.13 | $8.47 |
| Resistance Level | $17.05 | $8.54 |
| Average True Range (ATR) | 0.76 | 0.05 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 79.06 | 24.52 |
Price Performance
Historical ComparisonAbout ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.